Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Sep 12;40(9):908-910.
doi: 10.1016/j.ccell.2022.08.018.

Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity

William A Freed-Pastor  1 , Andrew J Aguirre  2
Affiliations
Free article
Comment

Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity

William A Freed-Pastor et al. Cancer Cell. .
Free article

Abstract

Covalent inhibitors of oncogenic KRASG12C have demonstrated impressive clinical responses; however, therapeutic resistance has been commonly observed. In this issue, Zhang and colleagues demonstrate that small molecule KRASG12C inhibitors can generate haptenated major histocompatibility complex (MHC) class I:peptide complexes, which represent attractive targets for immune-based therapies to combat pharmacologic resistance.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests A.J.A. has consulted for Arrakis Therapeutics, Syros Pharmaceuticals, Boehringer Ingelheim, T-knife Therapeutics, AstraZeneca, Mirati Therapeutics, Revolution Medicines, Anji Pharmaceuticals, and Merck & Co., Inc. A.J.A. consults for and holds equity in Riva Therapeutics. A.J.A. has research funding from Mirati Therapeutics, Syros Pharmaceuticals, Bristol Myers Squibb, Revolution Medicines, Novartis, Novo Ventures and Deerfield, Inc. W.A.F-P. has consulted for PMV Pharma and holds equity in Regeneron. W.A.F-P. receives research support from Arcus Biosciences and Apexigen.

Comment on

LinkOut - more resources